Latest Articles

Publication Date
Ovarian Precancerous Lesions and Their Molecular Landscape: A Structured Scoping Review Focused on STIC and Related Precursors of Epithelial Ovarian Cancer.

Ovarian cancer remains one of the deadliest gynecologic malignancies because of late-stage diagnosis, biological heterogeneity, and the lack of effective early detection strategies. Epithelial ovarian cancer (EOC) comprises several histotypes, …

Published: Sept. 18, 2026, midnight
Exosomal miR-22-3p targets p53 to regulate endometrial epithelial cell function in the pathogenesis of endometriosis.

Endometriosis (EMs) is a widespread gynecological disease, affecting approximately 6-10% of females of child-bearing age. Despite its significant influence on women's health, the specific pathophysiology remains unclear. The enrichment of …

Published: Sept. 4, 2026, midnight
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report - EurekAlert!

Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report EurekAlert!

Published: Aug. 4, 2026, 7:14 p.m.
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report - eurekalert.org

Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report eurekalert.org

Published: Aug. 4, 2026, 7:14 p.m.
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology

Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology

Published: July 31, 2026, 8:06 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive

Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive

Published: July 31, 2026, 5:22 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com

Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com

Published: July 31, 2026, 5:22 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork

Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork

Published: July 31, 2026, 2:37 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com

Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com

Published: July 31, 2026, 2:37 p.m.
p53-mediated epigenetic regulation in the pathogenesis of endometriosis.

Endometriosis (EMs) is a common gynecological disorder affecting reproductive‑aged women, characterized by ectopic endometrial growth and chronic pelvic pain that severely impairs quality of life. Although its pathogenesis remains incompletely …

Published: July 21, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!